At the CCRI, we are committed to world-class catalysis research. We are looking forward to leveraging the capabilities of the Freeslate products in a wide range of applications.
Sunnyvale, CA (PRWEB) April 21, 2015
Freeslate, Inc., the leading provider of high-throughput research solutions for biopharmaceutical development, today announced that the Centre for Catalysis Research and Innovation (CCRI) at the University of Ottawa has acquired a Freeslate Core Module 3 (CM3) Reaction Screening System and Screening Pressure Reactor (SPR) to accelerate current research programs. The systems will be placed in the High-Throughput Experimentation Facility where they will be available to academic users and industrial collaborators/ partners who are pursuing excellence in catalysis research.
The CM3 Reaction Screening System and SPR are versatile research tools that allow hundreds of diverse reactions to be screened in a highly automated way with minimal material consumed. The Freeslate solutions in catalyst screening and testing are expected to significantly enhance research in several key programs in the areas of homogeneous and heterogeneous catalysis.
“At the CCRI, we are committed to world-class catalysis research,” said Roxanne Clément, the HTE manager at the CCRI. “We are looking forward to leveraging the capabilities of the Freeslate products in a wide range of applications.”
“We are very pleased with our ongoing relationship with the Centre for Catalysis Research and Innovation,” said John S. Senaldi, President and CEO of Freeslate. “The facility first started doing high-throughput catalyst research with the CM1, the predecessor to the CM3, back in 2004. The fact that they have chosen to continue with Freeslate as their research capabilities are expanding speaks to the value they place on our technology and the power of our systems.”
Freeslate's CM3 Reaction Screening System and SPR products are designed to accelerate innovation by screening a broader experimental space with hundreds of catalysts and reaction conditions, limiting simplifying assumptions, and delivering non-intuitive results. These products enable high-throughput development of heterogeneous catalysts and reaction conditions in relevant industries including pharmaceuticals, petrochemicals, and biorenewables. Freeslate’s team of application scientists and engineers collectively apply decades of hands-on catalyst development experience and proven expertise, maximizing the value of the high-throughput research solutions offered.
Freeslate is a privately held company providing laboratory automation products that dramatically improve the productivity and innovation of drug development organizations. For more than a decade, Freeslate has been working with customers to automate complex chemical research processes. Our resulting product line includes solutions for protein and vaccine drug formulation development, small molecule solubility, and polymorph screening and process chemistry. We start with a scientific understanding of our customer’s bottlenecks and utilize our robust and proprietary automation platforms and integrated Lab Execution and Analysis (LEA) software suite to deliver solutions that make a difference. The company is headquartered in Sunnyvale, California, with direct sales and service in North America, Europe, and Asia. For more information, visit http://www.freeslate.com.